scholarly journals Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update Summary

2017 ◽  
Vol 13 (12) ◽  
pp. 822-824 ◽  
Author(s):  
Catherine Van Poznak ◽  
Mark R. Somerfield ◽  
Beverly Moy
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Clinical Oncology ◽  
Cancer Care ◽  
Metastatic Breast ◽  
American Society

Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update

2017 ◽  
Vol 35 (35) ◽  
pp. 3978-3986 ◽  
Author(s):  
Catherine Van Poznak ◽  
Mark R. Somerfield ◽  
William E. Barlow ◽  
J. Sybil Biermann ◽  
Linda D. Bosserman ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Pain Management ◽  
Supportive Care ◽  
Bone Metastases ◽  
Cancer Care ◽  
Bone Pain ◽  
Metastatic Breast ◽  
American Society

Purpose To update, in collaboration with Cancer Care Ontario (CCO), key recommendations of the American Society of Clinical Oncology (ASCO) guideline on the role of bone-modifying agents (BMAs) in metastatic breast cancer. This focused update addressed the new data on intervals between dosing and the role of BMAs in control of bone pain. Methods A joint ASCO-CCO Update Committee conducted targeted systematic literature reviews to identify relevant studies. Results The Update Committee reviewed three phase III noninferiority trials of dosing intervals, one systematic review and meta-analysis of studies of de-escalation of BMAs, and two randomized trials of BMAs in control of pain secondary to bone metastases. Recommendations Patients with breast cancer who have evidence of bone metastases should be treated with BMAs. Options include denosumab, 120 mg subcutaneously, every 4 weeks; pamidronate, 90 mg intravenously, every 3 to 4 weeks; or zoledronic acid, 4 mg intravenously every 12 weeks or every 3 to 4 weeks. The analgesic effects of BMAs are modest, and they should not be used alone for bone pain. The Update Committee recommends that the current standard of care for supportive care and pain management—analgesia, adjunct therapies, radiotherapy, surgery, systemic anticancer therapy, and referral to supportive care and pain management—be applied. Evidence is insufficient to support the use of one BMA over another. Additional information is available at www.asco.org/breast-cancer-guidelines and www.asco.org/guidelineswiki .

scholarly journals American Society of Clinical Oncology Clinical Practice Guideline Update: Recommendations on the Role of Bone-Modifying Agents in Metastatic Breast Cancer

2011 ◽  
Vol 7 (2) ◽  
pp. 117-121 ◽  
Author(s):  
Catherine H. Van Poznak ◽  
Jamie H. Von Roenn ◽  
Sarah Temin
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Clinical Practice ◽  
Bone Metastases ◽  
Clinical Oncology ◽  
Clinical Practice Guideline ◽  
Practice Guideline ◽  
Metastatic Breast ◽  
American Society

Journal of Clinical Oncology recently published ASCO's update to its guideline on the use of bone-modifying agents for patients with bone metastases, the scope of which was narrowed to the use of bone-modifying agents for patients with evidence of bone metastases.

Breast Cancer Care: Developments in 1998

1998 ◽  
Vol 5 (4) ◽  
pp. 338-345
Author(s):  
John Horton
Keyword(s):  
Breast Cancer ◽  
Cancer Care ◽  
Metastatic Breast ◽  
The United States ◽  
Axillary Node ◽  
Standards Of Care ◽  
Sources Of Information ◽  
Breast Cancer Care ◽  
Mortality And Morbidity ◽  
American Society

Background Breast cancer is a significant cause of mortality and morbidity worldwide, although death rates in the United States and some other countries are beginning to fall. Methods Several sources of information in 1998, including publications and presentations at the 1998 meeting of the American Society of Clinical Oncology, are pertinent to contemporary breast cancer care. Results It is now possible to prescribe hormonal therapy that will reduce the incidence of breast cancer. Methods are available to reduce the morbidity from axillary node dissection, and improvements in adjuvant therapy and management of metastatic breast cancer are now at hand. Conclusions The information presented provides a broad-based platform for new standards of care for breast cancer that will serve as a sound base for further progress in this important disease.

Sign in / Sign up

Export Citation Format

Share Document